The efficacy of combined treatment of secondary hyperthyroidism in pre-dialysis chronic kidney disease patients

Abstract

Background. It is well known that chronic kidney di­sease (CKD) patients develop mineral and bone disturbances which lead to the development of renal osteodystrophy and its complications. Secondary hyperthyroidism is the main reason for the deve­lopment of mineral and bone disoders in these patients. The purpose of the study was to evaluate the efficacy of combined therapy with Alfacalcidol and Quercetin in the treatment of secondary hyperthyroidism in pre-dialysis CKD patients. Materials and me­thods. 61 patients with CKD 3 and 4 stages aged 20–78 years were included in the study. Patients were divided into 2 groups: 35 patients received combined treatment with Alfacalcidol and Quercetin granules, and 26 patients received standard treatment with calcium carbonate. Indices of calcium, phosphorus, magnesium, and alkaline phosphatase were analyzed by photocolometry method and parathyroid hormone (PTH) by immune assay method. Statistical analysis was performed in the Statistica 5.0 program (StatSoft Inc., USA). Results. It was shown that intake of Alfacalcidol (0,25–0,5 mcg daily) and Quercetin granules 1.0 g three times per day provided normalization of calcium-phosphorous homeostasis, correction of hyperthyroidism but also has pronounced analgesic effect as compared with patients receiving monotherapy with calcium carbonate. Conclusions. Combined treatment with Alfacalcidol and Quercetin granules in predialysis CKD patients with se­condary hyperthyroidism leads to calcium and phosphorus metabolism normalization, correction of secondary hyperthyroidism, and has an analgesic effect.